Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting
September 20, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American...
Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients
September 01, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that its collaboration with Dr. Iñaki Sanz at Emory...
Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA
August 04, 2022 16:06 ET
|
Exagen Inc.
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the launch of a prospective clinical study designed to...
Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference
July 25, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 42nd Annual...
Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility
July 05, 2022 08:25 ET
|
Exagen Inc.
SAN DIEGO, July 05, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced new robust, real-world evidence confirming AVISE® testing...
Exagen Inc. Expands Coverage with MediNcrease
June 09, 2022 08:25 ET
|
Exagen Inc.
SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the addition of Exagen Inc. to MediNcrease Health Plans,...
Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
May 26, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 42nd Annual Growth...
Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
May 16, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE® Lupus are a contracted covered...
Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test
May 11, 2022 16:06 ET
|
Exagen Inc.
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Medicare Administrative Contractor (MAC) Noridian has...
Exagen Inc. Reports First Quarter 2022 Results
May 11, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2022. ...